6 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 6 separate news trends connected to Autoimmune Diseases, spanning August 4, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 45 article observations and 44 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
A cancer therapy has shown promise in treating severe rheumatoid arthritis, offering new hope to patients.
Scientists have discovered a new ability of T cells that could change how we understand autoimmune problems.
Boulevard Bio debuts with $65 million in funding to advance a pipeline of targeted antibody therapies focused on autoimmune disease.
New research links tissue-resident immune cells to genetic risk in autoimmune and lung diseases